Skip to content

Development and Effectiveness Evaluation of an AI-HEALS-Based Medication Adherence Intervention for Secondary Prevention in Ischemic Stroke Patients

Development and Evaluation of an AI-HEALS-Based Medication Adherence Intervention for Secondary Prevention in Thrombolysis-Treated Ischemic Stroke Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101457
Enrollment
Unknown
Registered
2025-04-25
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Interventions

AI-HEALS Mobile Health Education Group:The intervention approach primarily based on AI-HEALS utilizes the WeChat social platform, adopting an "Internet + Nursing Services" model. This comprehensive sy
Control Group:Patients in the control group will not receive any controlled interventions. They will only receive standard neurology department care protocols for ischemic stroke (IS) patients, includ

Sponsors

Linyi Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for first-ever ischemic stroke; 2. Have achieved clinical stability after intravenous thrombolytic therapy (IVT); 3. Age >= 18 years; 4. Proficient in using smartphones and mobile applications such as WeChat; 5. Signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients who developed cerebral hemorrhage after intravenous thrombolysis treatment; 2.Patients indicated for mechanical thrombectomy based on cerebral angiography (CTA) or other imaging examinations; 3.Patients with severe mental illness, consciousness disorders, or those unable to communicate effectively; 4.Patients with severe gastrointestinal bleeding, or those with severe insufficiency of heart, liver, or kidney functions; 5.Patients with cancer or hemorrhagic diseases.

Design outcomes

Primary

MeasureTime frame
Medication Adherence;

Secondary

MeasureTime frame
Blood Pressure;LDL-C;Quality of Life;

Countries

China

Contacts

Public ContactTeng Maoda

Linyi Central Hospital

15864832129@163.com+86 158 6483 2129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026